Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Dunn, M. Watson, Joanne Aitken, M. Hyde (2017)Systematic review of psychosocial outcomes for patients with advanced melanoma
D. Mayer, S. Birken, Devon Check, Ronald Chen (2015)Summing it up: An integrative review of studies of cancer survivorship care plans (2006‐2013)
J. Cormier, M. Ross, J. Gershenwald, Jeffrey Lee, P. Mansfield, Luis Camacho, Kevin Kim, K. Webster, D. Cella, J. Palmer (2008)Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer Therapy‐Melanoma questionnaire
C. Paul, E. Fradgley, Della Roach, H. Baird (2017)Impact of financial costs of cancer on patients - the Australian experience
C. Balch, J. Gershenwald, S. Soong, J. Thompson, M. Atkins, D. Byrd, A. Buzaid, A. Cochran, D. Coit, Shouluan Ding, A. Eggermont, K. Flaherty, P. Gimotty, J. Kirkwood, K. McMasters, M. Mihm, D. Morton, M. Ross, A. Sober, V. Sondak (2009)Final version of 2009 AJCC melanoma staging and classification.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 36
M. Callahan, H. Kluger, M. Postow, N. Segal, A. Lesokhin, M. Atkins, J. Kirkwood, S. Krishnan, R. Bhore, C. Horak, J. Wolchok, M. Sznol (2017)Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 4
(2006)From cancer patient to cancer survivor: lost in transition
D. Schadendorf, M. Amonkar, D. Stroyakovskiy, E. Levchenko, H. Gogas, F. Braud, J. Grob, I. Bondarenko, C. Garbe, C. Lebbé, J. Larkin, V. Chiarion-Sileni, M. Millward, A. Arance, M. Mandalà, K. Flaherty, P. Nathan, A. Ribas, C. Robert, M. Casey, D. Demarini, J. Irani, G. Aktan, G. Long (2015)Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
European journal of cancer, 51 7
D. Revicki, A. Eertwegh, P. Lorigan, C. Lebbé, G. Linette, C. Ottensmeier, S. Safikhani, M. Messina, A. Hoos, S. Wagner, S. Kotapati (2012)Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
Health and Quality of Life Outcomes, 10
J. Winstanley, T. Young, F. Boyle, M. Bergenmar, A. Bottomley, B. Burmeister, L. Campana, J. Garioch, M. King, D. Nikolić, L. Poll-Franse, R. Saw, J. Thompson, Edward White (2015)Cross-cultural development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module
Melanoma Research, 25
P. Schofield, K. Gough, K. Lotfi-Jam, S. Aranda (2012)Validation of the Supportive Care Needs Survey—short form 34 with a simplified response format in men with prostate cancer
K. Yabroff, Emily Dowling, G. Guy, M. Banegas, A. Davidoff, Xuesong Han, Katherine Virgo, T. McNeel, Neetu Chawla, D. Blanch-Hartigan, E. Kent, Chunyu Li, Juan Rodriguez, Janet Moor, Zhiyuan Zheng, A. Jemal, D. Ekwueme (2016)Financial Hardship Associated With Cancer in the United States: Findings From a Population-Based Sample of Adult Cancer Survivors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 3
J. Schachter, A. Ribas, G. Long, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, T. Petrella, O. Hamid, Honghong Zhou, S. Ebbinghaus, N. Ibrahim, C. Robert (2017)Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
The Lancet, 390
G. Long, Z. Eroglu, J. Infante, S. Patel, A. Daud, Douglas Johnson, R. Gonzalez, R. Kefford, O. Hamid, L. Schuchter, J. Cebon, W. Sharfman, R. McWilliams, M. Sznol, S. Redhu, E. Gasal, B. Mookerjee, J. Weber, K. Flaherty (2017)Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 7
D. Schadendorf, G. Long, D. Stroiakovski, B. Karaszewska, A. Hauschild, E. Levchenko, V. Chiarion-Sileni, J. Schachter, C. Garbe, C. Dutriaux, H. Gogas, M. Mandalà, J. Haanen, C. Lebbé, A. Mackiewicz, P. Rutkowski, J. Grob, P. Nathan, A. Ribas, M. Davies, Ying Zhang, M. Kaper, B. Mookerjee, J. Legos, K. Flaherty, C. Robert (2017)Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
European journal of cancer, 82
G. Deimling, K. Bowman, Samantha Sterns, Louis Wagner, B. Kahana (2006)Cancer‐related health worries and psychological distress among older adult, long‐term cancer survivors
F. Hodi, S. O'Day, D. McDermott, R. Weber, J. Sosman, J. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, Jessica Hassel, W. Akerley, A. Eertwegh, J. Lutzky, P. Lorigan, J. Vaubel, G. Linette, D. Hogg, C. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, Joseph Clark, J. Wolchok, J. Weber, Jason Tian, M. Yellin, G. Nichol, A. Hoos, W. Urba (2010)Improved survival with ipilimumab in patients with metastatic melanoma.
The New England journal of medicine, 363 8
Pricivel Carrera, H. Kantarjian, V. Blinder (2018)The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment
CA: A Cancer Journal for Clinicians, 68
M. Brennan, M. Brennan, J. Gormally, Phyllis Butow, Frances Boyle, F. Boyle, A. Spillane (2014)Survivorship care plans in cancer: a systematic review of care plan outcomes
British Journal of Cancer, 111
A. Rogiers, J. Cremer, Laila Salama, M. Ridder, J. Bernheim, B. Neyns, P. Theuns (2018)Psychosocial outcome and health-related quality of life (HRQoL) in advanced melanoma survivors.
Journal of Clinical Oncology, 36
J. Wolchok, V. Chiarion-Sileni, R. Gonzalez, P. Rutkowski, J. Grob, L. Cowey, C. Lao, J. Wagstaff, D. Schadendorf, P. Ferrucci, M. Smylie, R. Dummer, A. Hill, D. Hogg, J. Haanen, M. Carlino, O. Bechter, M. Maio, I. Márquez-Rodas, M. Guidoboni, G. McArthur, C. Lebbé, P. Ascierto, G. Long, J. Cebon, J. Sosman, M. Postow, M. Callahan, D. Walker, L. Rollin, R. Bhore, S. Hodi, J. Larkin (2017)Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
The New England Journal of Medicine, 377
D. Schadendorf, J. Larkin, J. Wolchok, F. Hodi, V. Chiarion-Sileni, R. Gonzalez, P. Rutkowski, J. Grob, C. Cowey, C. Lao, J. Wagstaff, M. Callahan, M. Postow, M. Smylie, P. Ferrucci, R. Dummer, A. Hill, F. Taylor, J. Sabater, D. Walker, S. Kotapati, A. Abernethy, G. Long (2017)Health-related quality of life results from the phase III CheckMate 067 study
European journal of cancer (Oxford, England : 1990), 82
P. Wright, Adam Smith, A. Keding, G. Velikova (2011)The Social Difficulties Inventory (SDI): development of subscales and scoring guidance for staff
M. Dieng, P. Butow, D. Costa, R. Morton, S. Menzies, S. Mireskandari, S. Tesson, G. Mann, A. Cust, N. Kasparian (2016)Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 36
J. Winstanley, Edward White, F. Boyle, J. Thompson (2013)What are the pertinent quality-of-life issues for melanoma cancer patients? Aiming for the development of a new module to accompany the EORTC core questionnaire
Melanoma Research, 23
J. Wolchok, H. Kluger, M. Callahan, M. Postow, N. Rizvi, A. Lesokhin, N. Segal, C. Ariyan, R. Gordon, Kathleen Reed, M. Burke, A. Caldwell, S. Kronenberg, B. Agunwamba, Xiaoling Zhang, I. Lowy, H. Inzunza, W. Feely, C. Horak, Q. Hong, A. Korman, J. Wigginton, A. Gupta, M. Sznol (2013)Nivolumab plus ipilimumab in advanced melanoma.
The New England journal of medicine, 369 2
A. Hauschild, J. Grob, L. Demidov, T. Jouary, R. Gutzmer, M. Millward, P. Rutkowski, C. Blank, W. Miller, E. Kaempgen, S. Martı́n-Algarra, B. Karaszewska, C. Mauch, V. Chiarion-Sileni, Anne-Marie Martin, S. Swann, P. Haney, B. Mirakhur, Mary Guckert, V. Goodman, P. Chapman (2012)Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
The Lancet, 380
David Levy, H. Dhillon, A. Lomax, Michael Marthick, C. McNeil, S. Kao, J. Lacey (2018)Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy
Supportive Care in Cancer, 27
G. Long, V. Atkinson, P. Ascierto, C. Robert, Jessica Hassel, P. Rutkowski, K. Savage, F. Taylor, C. Coon, I. Gilloteau, H. Dastani, I. Waxman, A. Abernethy (2016)Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study
Annals of Oncology, 27
J. Temel, J. Gainor, R. Sullivan, J. Greer (2018)Keeping Expectations in Check With Immune Checkpoint Inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 17
D. Schadendorf, R. Dummer, A. Hauschild, C. Robert, O. Hamid, A. Daud, A. Eertwegh, L. Cranmer, S. O'Day, I. Puzanov, J. Schachter, C. Blank, A. Salama, C. Loquai, J. Mehnert, D. Hille, S. Ebbinghaus, S. Kang, Wei Zhou, A. Ribas (2016)Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
European journal of cancer, 67
M. Mayer, K. Lang, S. Hurvitz, D. Lalla, V. Federico, M. Brammer, J. Menzin, D. Tripathy (2015)Symptom Burden and Quality of Life among Women with HER2+ Metastatic Breast Cancer
The Breast Journal, 21
J. Bauml, A. Troxel, C. Epperson, R. Cohen, K. Schmitz, C. Stricker, L. Shulman, A. Bradbury, J. Mao, C. Langer (2016)Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".
Lung cancer, 100
C. Robert, A. Ribas, O. Hamid, A. Daud, J. Wolchok, A. Joshua, W. Hwu, J. Weber, T. Gangadhar, R. Joseph, R. Dronca, A. Patnaik, H. Zarour, R. Kefford, P. Hersey, Xiaoyun Li, Scott Diede, S. Ebbinghaus, F. Hodi (2016)Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
Journal of Clinical Oncology, 12
J. Grob, M. Amonkar, B. Karaszewska, J. Schachter, R. Dummer, A. Mackiewicz, D. Stroyakovskiy, K. Drucis, F. Grange, V. Chiarion-Sileni, P. Rutkowski, M. Lichinitser, E. Levchenko, P. Wolter, A. Hauschild, G. Long, P. Nathan, A. Ribas, K. Flaherty, P. Sun, J. Legos, D. McDowell, B. Mookerjee, D. Schadendorf, C. Robert (2015)Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
The Lancet. Oncology, 16 13
N. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, N. Duez, A. Filiberti, H. Flechtner, S. Fleishman, J. Haes, S. Kaasa, M. Klee, D. Osoba, D. Razavi, Peter Rofe, S. Schraub, K. Sneeuw, M. Sullivan, F. Takeda (1993)The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
Journal of the National Cancer Institute, 85 5
L. Koch, L. Jansen, H. Brenner, V. Arndt (2013)Fear of recurrence and disease progression in long‐term (≥5 years) cancer survivors—a systematic review of quantitative studies
P. Ascierto, G. McArthur, B. Dréno, V. Atkinson, G. Liszkay, A. Giacomo, M. Mandalà, L. Demidov, D. Stroyakovskiy, L. Thomas, L. Cruz-Merino, C. Dutriaux, C. Garbe, Yibing Yan, M. Wongchenko, I. Chang, J. Hsu, D. Koralek, I. Rooney, A. Ribas, J. Larkin (2016)Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
The Lancet. Oncology, 17 9
F. Hodi, H. Kluger, M. Sznol, R. Carvajal, D. Lawrence, M. Atkins, J. Powderly, W. Sharfman, I. Puzanov, David Smith, P. Leming, E. Lipson, J. Taube, R. Anders, C. Horak, Joel Jiang, D. McDermott, J. Sosman, J. Brahmer, D. Pardoll, S. Topalian (2016)Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
Cancer Research, 76
Purpose Immune checkpoint inhibitors (ICI) and BRAF and MEK inhibitors (BMi) have improved survival in metastatic melanoma (MM). However, the experience of long-term responders remains undescribed. This study characterised survivorship issues faced by long-term responders to ICI or BMi. Methods Patients with MM, aged ≥ 18 years old, ≥ 6 months post-ICI or BMi initiation with an objective response or stable disease. A 72-question survey assessed physical and psychological effects, impact on lifestyle, access to information, satisfaction with care, and availability of supports. Results One hundred and five of 120 (88%) patients completed the survey (ICI 69/BMI 36). For the ICI cohort, 39 (57%) were receiving ongoing treatment, 17 ceased due to toxicity and 13 due to a sustained response. For the BMi cohort, 31 (85%) were receiving ongoing treatment, 4 ceased due to toxicity and 1 due to a sustained complete response. At data cut-off on 18 December 2018, median PFS (range) was 2.5 years (1.3–8.5) for ICI and 3.1 years (0.6–7.3) for BMi. Long-term toxicities included dry/ itchy skin (ICI 51, 74%/ BMi 25, 69%), arthralgias (ICI 30, 58%/ BMi 23, 64%) and fatigue (ICI 62, 90%/ BMi 33, 92%). Psychological morbidity was common, including anxiety awaiting
Journal of Cancer Survivorship: Research and Practice – Springer Journals
Published: Jun 4, 2019
Access the full text.
Sign up today, get DeepDyve free for 14 days.